No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
531 |
4. Check minimum number of eventsNone |
531 |
5. Include endpointsNone |
531 |
6. Filter based on genotype QC (FinnGen only) |
517 |
Control definitions (FinnGen only)
- Control exclude
- L12_URTICARIAERYTHEMA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Universal erythroderma, KELA reimbursement
based on the number of shared cases.
Similar with more cases:
- Atopic dermatitis, strict definition with reimbursement
- Urticaria and erythema
- Diseases of the skin and subcutaneous tissue
- Any reimbursement code in KELA
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3118 | 1019 | 2077 |
| Only index persons | 2650 | 908 | 1742 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.03 | 0.06 |
| Only index persons | 0.06 | 0.03 | 0.07 |
| Median age at first event (years) | |||
| Whole population | 50.11 | 51.31 | 49.42 |
| Only index persons | 48.21 | 49.83 | 47.37 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 517 | 190 | 327 |
| Unadjusted period prevalence (%) | 0.12 | 0.07 | 0.15 |
| Median age at first event (years) | 47.45 | 46.91 | 47.77 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 531
- Matched controls
- 5310
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E000001, ,
ATC
26.2
319.5
405
581
D07XC01
ATC
betamethasone; topical
23.6
319.0
339
369
134
Kela drug reimbursment
General erythroderma
+∞
307.7
531
*
D05AX52
ATC
calcipotriol, combinations; topical
45.2
307.7
278
126
D05AX02
ATC
calcipotriol; topical
81.2
307.7
280
72
L40.0
ICD-10 Finland
Psoriasis vulgaris
99.7
307.7
330
86
L04AX03
ATC
methotrexate; systemic
26.1
307.7
299
250
D05BB02
ATC
acitretin; oral
202.6
307.7
342
47
E000003, ,
ATC
32.3
271.5
194
93
D05AX03
ATC
calcitriol; topical
85.2
259.1
139
22
E000002, ,
ATC
17.8
245.2
263
278
L40.5
ICD-10 Finland
Arthropathic psoriasis
65.9
231.7
130
26
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
95.6
226.4
119
16
L04AD01
ATC
ciclosporin; systemic
53.0
214.4
126
31
E0000UV, ,
ATC
42.3
214.0
499
1430
D07AC01
ATC
betamethasone; topical
26.3
213.9
474
1274
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
44.5
209.6
129
38
D07AD01
ATC
clobetasol; topical
13.3
207.0
298
467
D07AB08
ATC
desonide; topical
14.3
204.7
248
307
TQW80
NOMESCO Finland
Local dermatologic skincare
32.7
180.6
122
48
L40.8
ICD-10 Finland
Other psoriasis
87.6
177.1
94
13
317
Kela drug reimbursment
Topical pimecrolimus and tacrolimus
41.1
170.0
106
32
L40.9
ICD-10 Finland
Psoriasis, unspecified
55.6
166.6
96
21
319
Kela drug reimbursment
Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)
258.0
165.5
162
9
L04AA01
ATC
[U] ciclosporin
65.7
158.2
88
16
D07AC13
ATC
mometasone; topical
10.0
154.3
365
960
D07AB02
ATC
hydrocortisone butyrate; topical
9.5
148.4
361
969
D11AH01
ATC
tacrolimus; topical
71.2
144.2
79
13
E000006, ,
ATC
14.2
144.0
150
143
D02AE01
ATC
carbamide; topical
13.1
139.0
154
161
D02AX
ATC
Other emollients and protectives
22.1
136.6
107
60
L40
ICD-10 Finland
Psoriasis
29.9
131.3
90
36
L20.0
ICD-10 Finland
Besnier prurigo
12.1
125.4
145
160
L01BA01
ATC
methotrexate; systemic
18.5
122.9
105
70
E000007, ,
ATC
13.8
122.1
126
117
L04AB04
ATC
adalimumab; parenteral
29.6
121.1
83
33
D07AA02
ATC
hydrocortisone; topical
8.1
117.0
213
407
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
9.3
112.6
165
246
D07BA04
ATC
hydrocortisone and antiseptics; topical
8.4
99.2
156
250
L26
ICD-10 Finland
Exfoliative dermatitis
+∞
99.1
92
*
N05BB01
ATC
hydroxyzine; systemic
11.0
98.0
117
133
M07.3
ICD-10 Finland
Other psoriatic arthropathies
38.2
87.9
55
16
D11AX14
ATC
[U] tacrolimus
55.1
87.2
50
10
D09AB01
ATC
zinc bandage without supplements; topical
28.1
86.8
60
24
D05AA
ATC
Tars
35.2
79.6
51
16
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
6.2
75.9
165
362
6961A
ICD-9 Finland
Psoriasis and similar disorders, Other psoriasis[PSORIASIS VULGARIS]
802.0
73.0
70
*
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
108.9
70.0
75
8
L04AB01
ATC
etanercept; parenteral
28.8
66.0
45
17
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
4.7
66.0
232
753
L04AC05
ATC
ustekinumab; parenteral
152.9
64.5
67
5
S91
ICPC
Psoriasis
26.1
58.1
41
17
XQ848
NOMESCO Finland
Dermatological photography
12.4
58.1
60
54
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
6.1
54.4
109
217
L04AC10
ATC
secukinumab; parenteral
91.1
52.1
57
7
E000004, ,
ATC
14.7
49.9
46
34
L04AC13
ATC
ixekizumab; parenteral
251.2
45.7
46
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.7
42.1
116
301
395
Kela drug reimbursment
Dupilumab
440.3
41.7
41
*
D11AH02
ATC
pimecrolimus; topical
81.5
40.6
45
6
H02AB06
ATC
prednisolone; systemic
3.4
40.0
333
1774
D11AH05
ATC
dupilumab; topical
+∞
39.0
37
*
XQ800
NOMESCO Finland
Prick test
6.1
39.0
74
138
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
5.0
37.3
89
204
D07AC14
ATC
methylprednisolone aceponate; topical
6.4
35.9
64
112
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
5.8
35.6
70
135
L30.3
ICD-10 Finland
Infective dermatitis
7.6
33.6
50
72
R06AE07
ATC
cetirizine; oral
3.0
33.5
277
1425
L04AC18
ATC
risankizumab; parenteral
181.2
33.1
34
*
XQ802
NOMESCO Finland
Epicutan test
7.5
32.3
48
69
L04AC16
ATC
guselkumab; systemic
343.3
32.2
32
*
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
9.9
31.3
37
40
R06AE09
ATC
levocetirizine; oral
3.8
30.7
112
352
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
10.1
30.0
35
37
L20
ICD-10 Finland
Atopic dermatitis
8.7
29.9
39
48
D07CC01
ATC
betamethasone and antibiotics; topical
3.6
29.5
117
388
L40.4
ICD-10 Finland
Guttate psoriasis
158.6
29.0
30
*
D07BC01
ATC
betamethasone and antiseptics; topical
3.7
28.2
106
339
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
147.5
26.9
28
*
69100
ICD-8 Finland
Infantile eczema and related conditions, Eczema atopicum. Prurigo Besnier. Eczema pruriginosum allergicum
10.2
25.2
29
30
L04AA32
ATC
apremilast; oral
250.8
23.8
24
*
D11AX15
ATC
[U] pimecrolimus
130.9
23.8
25
*
377
Kela drug reimbursment
Apremilast and dimethyl fumarate (psoriasis)
130.9
23.8
25
*
6960A
ICD-9 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
68.2
23.0
26
*
L40.1
ICD-10 Finland
Generalized pustular psoriasis
+∞
22.0
21
*
L04AX01
ATC
azathioprine; systemic
5.2
21.0
45
93
TQW99
NOMESCO Finland
Other minor procedure on skin
4.6
20.9
52
122
D05AC01
ATC
dithranol; topical
80.1
20.8
23
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.3
20.4
283
1740
D07XB05
ATC
dexamethasone; topical
6.4
20.1
34
56
R06AX27
ATC
desloratadine; oral
2.5
20.0
169
833
L04AA11
ATC
[U] etanercept
57.2
19.1
22
*
ZX112
NOMESCO Finland
Subcutaneous
6.9
18.5
29
44
A46
ICD-10 Finland
Erysipelas
2.8
17.6
104
428
WXQ12
NOMESCO Finland
Psoralen - Ultraviolet A therapy with local sensitivisation
43.6
17.4
21
5
SPAT1262
SPAT
Handing over of treatment supplies
2.6
17.3
118
522
C84.0
ICD-10 Finland
Mycosis fungoides
51.8
17.1
20
*
J01DA09
ATC
[U] cefadroxil
2.3
16.9
168
881
H02AB09
ATC
hydrocortisone; systemic
6.5
16.9
28
45
L20.9
ICD-10 Finland
Atopic dermatitis, unspecified
5.1
16.9
36
74
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.5
16.4
122
561
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
3.7
16.4
54
156
S01GX01
ATC
cromoglicic acid; ophthalmic
2.6
16.2
116
524
D05AX05
ATC
tazarotene; topical
62.0
15.8
18
*
WXQ10
NOMESCO Finland
Psoralen - Ultraviolet A therapy with systemic sensitivisation
+∞
15.7
15
*
A07EC01
ATC
sulfasalazine; oral, rectal
3.3
15.7
62
202
D05AX
ATC
Other antipsoriatics for topical use
87.7
15.6
17
*
H02AB07
ATC
prednisone; oral
2.7
15.5
93
384
ZY010
NOMESCO Finland
Hospital outpatient
4.0
15.4
45
119
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
5.3
15.4
32
64
J01FF01
ATC
clindamycin; systemic
2.2
15.4
170
926
D07XB01
ATC
flumetasone; topical
20.8
15.2
22
11
69600
ICD-8 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
58.4
14.9
17
*
WQ031, ,
NOMESCO Finland
+∞
14.6
14
*
RS340, ,
NOMESCO Finland
+∞
14.6
14
*
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.0
14.1
67
243
J01DA01
ATC
[U] cefalexin
2.1
14.1
342
2477
NH3EA
NOMESCO Finland
Feet X-ray examination with load
10.5
13.6
26
26
L04AC21
ATC
bimekizumab; systemic
+∞
13.6
13
*
D11AH04
ATC
alitretinoin; oral
+∞
13.6
13
*
M07.0
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
143.5
13.5
14
*
D07AB01
ATC
clobetasone; topical
4.7
13.5
32
72
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.6
12.9
86
373
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
5.5
12.4
24
45
C01CA24
ATC
epinephrine; parenteral
3.5
12.3
44
134
SPAT1263
SPAT
Sampling
1.9
11.9
223
1449
H04.10
ICD-10 Finland
Dry eye syndrome
2.7
11.8
66
261
L04AA13
ATC
[U] leflunomide
5.9
11.6
21
37
J30.10
ICD-10 Finland
Allergic rhinitis due to pollen
3.7
11.5
37
105
XX9XT
NOMESCO Finland
Other radiological intervention
+∞
11.5
11
*
J01DB01
ATC
cefalexin; oral
2.3
11.4
440
3622
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.8
11.4
61
236
6918B
ICD-9 Finland
Atopic dermatitis and related conditions, Other atopic dermatitis and related conditions[ECZEMA ATOPICUM]
13.1
11.2
19
15
B07.9
ICD-10 Finland
Verruca simplex
4.3
11.2
29
70
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.4
11.1
87
405
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.4
10.9
81
369
R06AX26
ATC
fexofenadine; oral
3.1
10.1
43
146
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.8
10.1
221
1489
J30.3
ICD-10 Finland
Other allergic rhinitis
4.3
10.0
26
63
RJ420, ,
NOMESCO Finland
17.1
9.9
15
9
L27.2
ICD-10 Finland
Dermatitis due to ingested food
26.6
9.9
13
5
A41.9
ICD-10 Finland
Sepsis, unspecified
4.0
9.8
28
73
L08.0
ICD-10 Finland
Pyoderma
13.7
9.7
16
12
9700/3-C44.9
ICD-O-3
Mycosis fungoides of skin, NOS
101.8
9.4
10
*
299, ,
Kela drug reimbursment
101.8
9.4
10
*
WQ066, ,
NOMESCO Finland
+∞
9.4
9
*
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
22.2
9.4
13
6
R06AX13
ATC
loratadine; oral
2.2
9.3
82
401
D06AX01
ATC
fusidic acid; topical
2.5
9.2
61
262
L40.3
ICD-10 Finland
Pustulosis palmaris et plantaris
10.3
9.1
17
17
J02AB02
ATC
ketoconazole; oral
4.2
9.1
24
59
RJ411, ,
NOMESCO Finland
12.8
8.9
15
12
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
1.9
8.9
141
853
J45.0
ICD-10 Finland
Predominantly allergic asthma
2.6
8.9
54
223
N06AA12
ATC
doxepin; systemic
3.0
8.8
40
141
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.8
8.8
204
1384
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.8
8.7
213
1468
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
2.2
8.7
75
363
SPAT1254
SPAT
Administration of medicine
2.2
8.7
83
419
SPAT1249
SPAT
Treatment-related counselling outside office
1.8
8.5
196
1327
L44.0
ICD-10 Finland
Pityriasis rubra pilaris
91.5
8.4
9
*
Q80.8
ICD-10 Finland
Other congenital ichthyosis
+∞
8.4
8
*
6929X
ICD-9 Finland
Contact dermatitis and other eczema, Unspecified cause[DERMATITITIS ARTEFACTA NUD]
33.9
8.1
10
*
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
2.6
8.1
47
190
A10BA02
ATC
metformin; oral
1.8
8.1
161
1042
RJ421, ,
NOMESCO Finland
22.4
8.0
11
5
N17.9
ICD-10 Finland
Acute renal failure, unspecified
3.3
7.9
30
95
QAA25
NOMESCO Finland
Destruction of lesion of head or neck
4.3
7.8
20
48
L50.8
ICD-10 Finland
Other urticaria
45.7
7.7
9
*
103
Kela drug reimbursment
Diabetes, insulin-treated
1.8
7.7
152
978
RS121, ,
NOMESCO Finland
12.1
7.6
13
11
L27.0
ICD-10 Finland
Generalized skin eruption due to drugs and medicaments
9.0
7.6
15
17
D07AC03
ATC
desoximetasone; topical
6.1
7.4
19
32
215
Kela drug reimbursment
Diabetes, non-insulin-treated
1.8
7.4
136
855
M07.2*L40.5
ICD-10 Finland
Psoriatic spondylitis
81.2
7.4
8
*
D05AD01
ATC
trioxysalen; topical
81.2
7.4
8
*
E66.8
ICD-10 Finland
Other obesity
3.2
7.4
30
99
J45.9
ICD-10 Finland
Asthma, unspecified
1.9
7.4
98
557
SPAT1312
SPAT
General health counselling
1.7
7.4
155
1015
T90
ICPC
Diabetes non-insulin dependent
1.8
7.2
129
805
RS211, ,
NOMESCO Finland
30.5
7.2
9
*
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
20.3
7.2
10
5
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
6.2
7.1
18
30
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
2.7
7.1
38
147
ZXC50
NOMESCO Finland
Cryotherapy
3.5
7.1
24
71
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
2.7
7.0
38
148
L28.1
ICD-10 Finland
Prurigo nodularis
14.0
6.9
11
8
R06AX22
ATC
ebastine; oral
2.0
6.8
83
458
WXQ24
NOMESCO Finland
UVB/UVA light therapy
40.6
6.8
8
*
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
3.4
6.8
24
73
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
1.8
6.7
104
619
6929B
ICD-9 Finland
Contact dermatitis and other eczema, Unspecified cause[ECZEMA INFECTIOSUM]
22.8
6.7
9
*
L01.1
ICD-10 Finland
Impetiginization of other dermatoses
22.8
6.7
9
*
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
1.7
6.7
169
1159
D07CA01
ATC
hydrocortisone and antibiotics; topical
2.0
6.7
73
387
SPAT1310
SPAT
Counselling related to known health issue
1.7
6.5
154
1036
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.7
6.5
148
986
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
1.7
6.5
131
844
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
2.4
6.4
43
186
I10
ICD-10 Finland
Essential (primary) hypertension
1.6
6.4
304
2422
E0001A1, ,
ATC
4.1
6.4
17
42
L50.9
ICD-10 Finland
Urticaria, unspecified
5.6
6.3
17
31
C84.1
ICD-10 Finland
Sézary disease
+∞
6.3
6
*
75720
ICD-8 Finland
Congenital anomalies of skin, hair and nails, Iethyosis congenita
+∞
6.3
6
*
WQ053, ,
NOMESCO Finland
+∞
6.3
6
*
Q80.2
ICD-10 Finland
Lamellar ichthyosis
+∞
6.3
6
*
E000005, ,
ATC
27.0
6.2
8
*
SPAT1305
SPAT
Counselling and guidance related to physical exercise
2.3
6.2
49
229
L23.8
ICD-10 Finland
Allergic contact dermatitis due to other agents
12.7
6.1
10
8
RS221, ,
NOMESCO Finland
6.1
6.0
15
25
J01DB05
ATC
cefadroxil; oral
2.8
6.0
30
112
J45
ICD-10 Finland
Asthma
2.2
6.0
50
238
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
382
1934
4.48
56.24
13.1
5.9
3.71
2.86
%
7.44
377
1822
63
64
11.03
56.21
3.0
3.2
4.06
4.27
e9/l
0.26
63
64
64
67
10.72
55.91
3.1
3.4
56.06
56.21
%
0.02
64
67
384
2000
4.32
53.08
13.5
6.0
27.62
27.26
%
0.28
378
1891
379
1970
4.23
52.19
12.9
5.7
56.74
57.59
%
0.83
373
1868
422
2382
4.76
51.30
14.4
9.6
4.10
4.17
e9/l
0.30
410
2094
64
123
5.78
32.57
1.9
1.5
0.02
0.10
iu/ml
—
5
29
87
221
4.51
32.00
1.9
1.3
3320.79
215.84
u/ml
3.86
80
196
203
1069
2.46
21.01
5.2
3.7
0.00
0.01
estimate
0.50
97
346
106
416
2.93
19.69
4.7
3.4
—
—
—
0
0
413
3032
2.63
19.41
6.2
3.9
13.93
11.76
mm/h
2.07
386
2804
422
3162
2.63
18.42
12.0
7.9
82.50
77.67
u/l
1.40
409
2972
24
13
19.27
16.14
1.9
1.2
9.02
8.98
ug/l
0.01
24
13
105
463
2.58
15.33
3.1
2.5
1.65
1.80
%
1.09
91
421
103
454
2.57
15.04
4.0
4.2
235.03
236.06
u/l
0.04
92
431
247
1572
2.07
14.82
5.4
3.6
—
—
—
0
0
290
1991
2.01
13.74
5.2
3.5
0.00
0.00
estimate
0.50
104
383
289
1989
1.99
13.52
6.5
4.8
0.00
0.00
estimate
-0.00
106
361
290
2013
1.97
13.07
5.2
3.5
0.00
0.00
estimate
-0.00
98
342
16
5
32.91
12.63
2.1
1.2
—
—
—
0
0
25
28
9.31
12.37
1.5
1.3
22.95
26.24
%
0.12
11
21
146
811
2.10
12.20
1.9
1.7
118103835.36
22302590.79
pmol/l
0.37
116
695
75
316
2.60
11.89
5.3
4.6
1.21
1.22
mmol/l
0.50
66
283
123
674
2.07
10.49
3.1
3.5
0.81
0.82
mmol/l
0.37
113
637
38
117
3.42
10.47
2.2
1.7
—
—
—
0
0
22
45
5.06
10.35
2.1
2.7
32.91
33.56
pg
0.28
22
45
145
849
1.97
10.26
3.2
2.5
4.69
4.14
e6/l
0.31
134
759
20
41
5.03
9.38
1.2
1.4
—
—
—
0
0
21
45
4.82
9.37
1.8
1.4
62.11
63.82
%
—
9
39
46
170
2.87
9.35
1.9
2.1
0.93
1.98
ug/l
0.88
38
153
70
322
2.35
9.14
1.8
3.0
66.63
66.45
g/l
0.06
58
294
18
26
7.13
7.83
1.8
2.2
—
—
—
0
0
189
1290
1.72
7.81
4.4
3.7
15.87
8.52
mg/mmol
0.94
117
863
73
371
2.12
7.47
2.9
2.0
270.16
384.05
nmol/l
6.38
67
343
262
1970
1.65
7.39
16.1
13.8
1.18
1.25
inr
0.87
107
565
226
1639
1.66
7.33
4.1
3.7
29.53
40.71
ng/l
1.53
164
1143
238
1759
1.64
7.10
5.8
4.8
34.22
35.71
g/l
3.25
218
1654
148
968
1.73
7.01
2.6
2.0
3.49
3.09
mg/l
0.89
117
842
165
1116
1.69
6.90
2.9
2.7
5430.50
7903.82
umol/l
0.27
145
984
19
49
3.98
6.76
1.2
1.1
—
—
—
0
0
31
111
2.90
6.70
1.5
1.2
—
—
—
0
0
277
2165
1.58
6.31
6.3
6.8
11.28
11.56
umol/l
0.16
263
2067
10
8
12.71
6.10
2.0
1.9
—
—
—
0
0
97
583
1.81
6.07
2.9
2.3
2.41
2.32
g/l
0.65
85
541
91
546
1.80
5.71
6.7
5.3
1.08
1.01
mmol/l
1.38
86
507
129
857
1.67
5.63
1.3
1.2
4.06
1.27
u/ml
0.65
43
234
183
1328
1.58
5.57
3.4
3.1
7.56
8.20
mmol/l
1.16
145
1120
464
4179
1.87
5.52
21.9
14.3
20.54
24.53
mg/l
2.11
407
3317
201
1508
1.54
5.20
4.3
3.1
—
—
—
0
0
27
105
2.66
5.05
1.3
1.7
—
—
—
0
0
110
720
1.67
5.04
2.1
1.7
1256.42
1178.07
nmol/l
0.44
83
560
23
82
2.89
5.04
2.3
2.2
16.04
16.20
%
0.06
11
43
90
559
1.73
5.00
3.0
2.3
22.41
23.25
%
0.21
78
485
179
1324
1.53
4.88
2.6
2.5
51.05
60.90
u/l
1.80
166
1239
99
636
1.68
4.86
3.1
2.3
12.69
13.24
umol/l
0.31
89
592
173
1273
1.53
4.82
3.7
3.1
53.51
106.71
e6/l
0.46
149
967
67
386
1.84
4.78
2.7
2.2
0.20
0.21
g/l
0.56
60
358
15
36
4.26
4.55
1.5
1.7
—
—
—
0
0
19
65
2.99
4.48
1.5
1.6
—
—
—
0
0
71
1106
0.59
4.25
2.9
2.8
0.56
0.76
ug/l
2.50
45
707
21
80
2.69
4.11
1.5
1.9
—
—
—
0
0
203
1587
1.45
4.06
2.6
2.2
72.19
75.68
nmol/l
1.09
183
1418
410
3659
1.53
4.05
26.8
17.0
14.54
14.87
%
0.82
403
3608
29
131
2.28
4.00
2.0
2.0
—
—
—
0
0
9
14
6.52
4.00
1.2
1.0
978.89
1587.71
miu/ml
—
9
14
294
2491
1.40
3.62
6.3
4.8
6.99
6.73
mmol/l
1.07
279
2333
29
137
2.18
3.62
1.9
3.9
64.84
106.79
mg/l
0.35
16
110
29
137
2.18
3.62
1.9
3.9
28.99
36.23
mg/l
0.67
17
112
25
111
2.31
3.60
1.4
1.7
—
—
—
0
0
15
51
3.00
3.60
1.5
1.7
—
—
—
0
0
25
112
2.29
3.53
1.4
1.8
—
—
—
0
0
8
14
5.78
3.35
3.9
5.4
—
—
—
0
0
180
1428
1.39
3.16
4.3
3.5
39.02
33.90
u/l
1.26
167
1356
13
44
3.00
3.15
1.3
1.7
8.37
4.24
umol/l
—
7
31
46
271
1.76
3.09
4.8
3.3
1.25
1.86
mmol/l
0.42
36
207
16
62
2.63
3.07
1.2
1.6
—
—
—
0
0
339
2991
1.37
3.00
4.5
3.6
14.66
14.79
pmol/l
0.40
300
2708
8
17
4.76
2.93
1.3
1.1
—
—
—
0
0
8
17
4.76
2.93
2.5
2.7
56462.50
39835.59
ug/l
—
8
17
116
1512
0.70
2.86
3.8
4.0
19.84
21.11
%
0.43
44
686
159
1256
1.38
2.82
2.1
2.1
143.39
338.71
u/l
1.74
150
1188
88
624
1.49
2.81
1.3
1.2
8.88
9.88
u/ml
0.05
43
240
16
66
2.47
2.73
1.3
1.3
—
—
—
0
0
58
380
1.59
2.65
4.5
3.3
2.25
2.03
mmol/l
0.17
42
312
33
186
1.83
2.59
1.8
1.7
1.60
1.53
g/l
0.13
25
162
9
25
3.64
2.58
1.2
1.6
—
—
—
0
0
9
25
3.64
2.58
1.2
1.6
—
—
—
0
0
147
1163
1.37
2.56
3.6
3.0
0.33
0.54
e6/l
1.08
128
871
235
1994
1.32
2.55
8.3
6.9
1.19
1.21
mmol/l
2.08
171
1719
196
1623
1.33
2.51
2.0
1.9
91.38
94.48
pmol/l
0.46
117
867
10
32
3.16
2.44
1.8
3.2
—
—
—
0
0
11
38
2.93
2.42
1.4
1.2
—
—
—
0
0
120
927
1.38
2.41
1.6
1.7
1.34
1.20
mg/l
0.18
93
713
431
4011
1.40
2.35
23.5
13.0
83.75
82.25
ml/min/173m2
0.65
385
3317
21
105
2.04
2.34
1.4
1.5
0.73
0.90
nmol/l
0.66
16
94
16
72
2.26
2.29
1.2
1.6
—
—
—
0
0
46
296
1.61
2.28
1.7
1.5
—
—
—
0
0
149
1200
1.34
2.28
3.6
3.2
2787.05
1259.83
ng/l
0.71
123
1015
9
29
3.14
2.23
1.2
1.6
—
—
—
0
0
200
1689
1.30
2.16
3.2
2.6
146.56
146.34
ug/l
0.00
177
1561
7
19
3.72
2.15
3.9
2.1
—
—
—
0
0
6
14
4.32
2.15
1.0
1.0
—
—
—
0
0
9
31
2.94
2.08
1.1
1.3
—
—
—
0
0
51
352
1.50
1.89
2.4
2.6
7.51
8.61
ug/l
0.17
40
315
89
681
1.37
1.89
1.9
1.9
—
—
—
0
0
16
79
2.06
1.87
1.3
1.6
—
—
—
0
0
7
23
3.07
1.80
1.3
1.0
—
—
—
0
0
61
822
0.71
1.77
3.3
3.9
627.60
401.74
ng/l
0.20
45
642
7
24
2.94
1.72
2.1
1.3
—
—
—
0
0
6
19
3.18
1.66
1.3
1.0
—
—
—
0
0
13
63
2.09
1.61
1.2
1.6
—
—
—
0
0
114
928
1.29
1.59
1.9
1.5
20.67
20.36
nmol/l
0.05
93
787
7
26
2.71
1.58
2.3
3.8
—
—
—
0
0
469
4498
1.37
1.52
21.9
10.3
29.77
28.39
u/l
0.82
464
4358
109
894
1.28
1.44
5.7
3.8
1.02
1.02
kg/l
0.04
15
128
6
22
2.75
1.44
1.0
1.1
189.33
236.10
iu/ml
—
6
22
9
39
2.33
1.43
1.1
1.2
—
—
—
0
0
22
134
1.67
1.41
2.5
2.4
237.50
121.39
ug/min
0.36
12
77
19
111
1.74
1.41
1.4
1.5
241.82
261.49
ug/g
0.16
11
67
9
41
2.22
1.37
3.6
2.1
—
—
—
0
0
5
17
2.96
1.36
1.8
3.8
232.20
204.06
u/l
—
5
17
28
412
0.66
1.32
1.7
1.7
—
—
—
0
0
17
98
1.76
1.32
1.5
1.4
—
—
—
0
0
204
1812
1.20
1.28
7.8
6.1
1.20
1.21
mmol/l
1.91
184
1662
396
3743
1.23
1.27
5.1
4.2
2.08
2.23
mu/l
0.20
353
3423
19
116
1.66
1.23
1.6
1.6
—
—
—
0
0
85
690
1.28
1.23
1.5
1.5
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
20
124
1.64
1.22
2.9
2.3
0.39
0.33
u/ml
0.29
12
67
22
141
1.58
1.19
1.3
2.4
11.76
10.68
g/l
0.16
15
126
0
33
0.00
1.16
0.0
1.1
—
—
—
0
0
15
87
1.75
1.16
1.6
1.5
—
—
—
0
0
467
4509
1.30
1.15
28.8
16.5
84.49
80.02
umol/l
1.20
467
4509
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
20
2.51
1.15
1.4
1.3
—
—
—
0
0
8
40
2.01
1.12
1.0
1.1
—
—
—
0
0
286
2640
1.18
1.12
6.1
4.1
1285.20
1603.61
e6/l
0.07
15
38
39
519
0.73
1.09
4.8
4.3
26.70
31.17
%
2.29
27
361
80
656
1.26
1.07
1.4
1.3
20.08
33.94
iu/ml
1.30
25
203
451
4345
1.25
1.07
21.7
16.3
3.99
3.99
mmol/l
0.19
438
4233
19
121
1.59
1.07
1.3
1.3
98.67
245.77
miu/ml
—
6
59
10
52
1.94
1.06
1.6
1.2
—
—
—
0
0
24
163
1.49
1.03
2.5
2.0
—
—
—
0
0
73
597
1.26
1.01
1.9
1.8
1.93
1.51
%
2.21
66
532
421
4037
1.21
0.99
5.9
3.9
1.45
1.33
mmol/l
2.05
397
3726
5
23
2.18
0.98
1.0
3.2
—
491.80
—
0
5
0
30
0.00
0.97
0.0
1.1
—
1.06
—
0
17
0
30
0.00
0.97
0.0
1.0
—
33.71
—
0
16
0
30
0.00
0.97
0.0
1.0
—
583.37
—
0
19
22
149
1.50
0.97
3.1
2.9
—
—
—
0
0
22
149
1.50
0.97
2.2
1.8
—
—
—
0
0
55
683
0.78
0.95
3.3
2.9
2.91
1.71
e6/l
0.41
34
381
309
2897
1.16
0.92
4.7
3.2
74.58
51.65
u/l
2.60
288
2716
448
4330
1.22
0.92
21.9
16.2
139.19
139.65
mmol/l
3.60
434
4223
405
3887
1.18
0.85
7.4
5.7
41.42
40.02
mmol/mol
1.94
368
3630
22
155
1.44
0.82
1.3
2.3
—
—
—
0
0
22
155
1.44
0.82
1.3
2.3
3.51
3.70
g/l
0.30
15
141
22
155
1.44
0.82
1.3
2.3
7.13
7.38
g/l
0.21
15
141
14
211
0.65
0.80
2.3
1.7
—
—
—
0
0
8
48
1.68
0.79
1.3
1.4
—
—
—
0
0
13
198
0.65
0.78
1.2
1.3
—
—
—
0
0
7
38
1.85
0.73
1.0
1.5
—
—
—
0
0
146
1316
1.15
0.73
2.9
3.2
2.33
2.35
mmol/l
0.83
128
1167
9
57
1.59
0.71
1.4
2.0
—
—
—
0
0
7
41
1.72
0.70
1.4
1.9
—
—
—
0
0
7
41
1.72
0.70
1.4
1.9
—
—
—
0
0
7
41
1.72
0.70
1.4
1.9
—
—
—
0
0
174
1893
0.88
0.69
3.8
4.5
1.58
2.38
ug/l
2.51
155
1709
58
485
1.22
0.69
1.5
1.9
—
—
—
0
0
211
1956
1.13
0.69
3.2
2.6
—
—
—
0
0
35
439
0.78
0.69
1.7
1.5
—
—
—
0
0
58
489
1.21
0.65
12.4
7.1
—
—
—
0
0
5
29
1.73
0.64
2.8
3.2
27.60
65.78
u/ml
—
5
29
32
401
0.79
0.63
3.5
2.4
65.96
163.42
u/l
0.37
27
343
6
102
0.58
0.62
1.2
1.4
—
—
—
0
0
18
130
1.40
0.62
1.4
2.6
1.74
1.25
g/l
0.13
12
117
431
4190
1.15
0.61
6.2
4.3
4.47
4.61
mmol/l
2.11
408
3900
8
50
1.61
0.61
1.4
2.1
—
—
—
0
0
11
163
0.67
0.61
2.5
1.7
—
—
—
0
0
33
264
1.27
0.59
1.7
1.5
—
—
—
0
0
17
123
1.39
0.58
1.4
2.4
40.40
37.59
g/l
—
10
109
0
23
0.00
0.58
0.0
1.5
—
—
—
0
0
15
108
1.40
0.53
3.7
2.3
8521.98
3948.73
u/l
—
9
42
19
144
1.33
0.51
1.3
1.5
—
—
—
0
0
12
84
1.44
0.49
1.5
1.4
—
—
—
0
0
7
47
1.50
0.47
2.7
2.4
—
—
—
0
0
16
120
1.34
0.46
3.4
3.2
1.78
1.51
mg/l
0.52
16
110
55
479
1.17
0.46
1.5
1.9
—
—
—
0
0
11
77
1.44
0.46
1.3
1.8
—
—
—
0
0
11
77
1.44
0.46
1.3
1.8
—
—
—
0
0
5
31
1.62
0.43
1.4
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.8
—
60.83
—
0
15
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
13
97
1.35
0.40
1.4
1.3
—
3.04
—
0
17
8
61
1.32
0.39
1.0
1.0
1.72
1.50
g/l
—
8
53
7
105
0.66
0.39
1.4
1.1
—
—
—
0
0
5
36
1.39
0.38
1.0
1.1
—
68.00
—
0
5
9
70
1.29
0.37
1.2
1.7
—
—
—
0
0
6
42
1.43
0.35
1.0
1.7
—
—
—
0
0
5
80
0.62
0.35
1.4
1.6
—
—
—
0
0
273
2637
1.07
0.33
2.8
3.0
—
—
—
0
0
18
146
1.24
0.32
1.3
2.3
2.65
3.05
g/l
1.34
11
132
7
53
1.32
0.31
1.3
1.6
—
—
—
0
0
7
53
1.32
0.31
1.3
1.6
—
—
—
0
0
66
721
0.90
0.30
3.0
2.7
1.19
1.14
e6/l
0.04
45
417
424
4168
1.09
0.30
5.3
4.3
1.34
1.41
mmol/l
2.49
391
3864
13
102
1.28
0.30
1.4
1.3
—
2.18
—
0
6
7
57
1.23
0.29
1.4
1.6
—
—
—
0
0
55
499
1.11
0.28
4.6
3.1
7.63
8.70
umol/l
0.29
44
450
10
128
0.78
0.27
1.2
2.1
11.12
12.27
mg/l
—
10
118
11
87
1.27
0.24
1.2
1.2
—
—
—
0
0
11
87
1.27
0.24
1.7
1.6
—
—
—
0
0
15
124
1.22
0.24
1.1
1.2
—
—
—
0
0
10
79
1.27
0.22
1.5
1.3
—
32.51
—
0
10
11
135
0.81
0.22
1.1
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
431
4256
1.07
0.21
5.7
4.8
2.66
2.75
mmol/l
1.42
398
3940
5
43
1.16
0.21
1.0
1.3
288.20
173.58
pmol/l
—
5
43
26
230
1.14
0.21
1.1
1.2
43.62
156.95
iu/ml
—
8
94
0
14
0.00
0.20
0.0
1.1
—
0.41
—
0
8
6
51
1.18
0.19
1.0
1.1
—
—
—
0
0
6
53
1.13
0.18
1.0
1.1
—
—
—
0
0
19
214
0.88
0.16
2.1
3.7
3.73
4.60
pmol/l
2.37
12
192
6
79
0.76
0.15
1.2
1.3
—
—
—
0
0
6
79
0.76
0.15
1.2
1.3
—
—
—
0
0
30
274
1.10
0.15
4.6
3.8
79.26
83.68
ng/l
0.15
23
243
38
410
0.92
0.15
2.3
1.9
—
—
—
0
0
10
83
1.21
0.15
1.0
1.2
14.44
54.95
u/l
—
10
72
9
80
1.13
0.15
1.3
1.2
—
—
—
0
0
53
502
1.06
0.12
9.8
7.6
1.40
0.93
mmol/l
0.30
39
409
102
985
1.04
0.12
3.5
2.4
—
—
—
0
0
16
178
0.90
0.11
1.0
1.0
—
—
—
0
0
10
115
0.87
0.10
1.1
1.1
—
—
—
0
0
13
146
0.89
0.10
1.2
1.6
—
—
—
0
0
43
453
0.94
0.10
2.1
2.0
—
—
—
0
0
5
44
1.14
0.10
1.0
1.1
—
—
—
0
0
411
4079
1.03
0.10
5.1
4.4
6.14
6.00
mmol/l
1.18
371
3738
5
45
1.11
0.10
4.2
3.0
3.88
3.39
nmol/l
—
5
45
10
114
0.87
0.09
1.1
1.1
—
—
—
0
0
109
1119
0.97
0.09
2.0
1.6
1.57
1.47
mmol/l
0.42
81
951
14
126
1.11
0.09
1.4
1.8
84.86
89.56
%
0.26
14
121
6
56
1.07
0.08
1.3
1.5
—
—
—
0
0
6
57
1.05
0.08
1.3
1.5
—
—
—
0
0
6
57
1.05
0.08
1.3
1.5
—
—
—
0
0
6
57
1.05
0.08
1.3
1.5
—
—
—
0
0
6
58
1.03
0.08
1.3
1.4
—
—
—
0
0
34
322
1.06
0.08
3.2
2.8
58.53
66.59
ml/min/173m2
0.73
15
132
8
92
0.87
0.07
1.3
1.6
—
—
—
0
0
8
93
0.86
0.06
1.3
1.3
—
—
—
0
0
473
4719
1.02
0.03
36.2
20.6
40.44
40.76
%
0.46
449
4415
43
424
1.02
0.00
3.5
4.7
10.22
39.95
ug/l
0.83
33
354
10
105
0.95
0.00
1.2
1.4
—
—
—
0
0
25
246
1.02
0.00
1.5
1.7
—
—
—
0
0
473
4726
1.01
0.00
36.2
20.5
4.48
4.56
e12/l
2.30
468
4600
6
65
0.92
0.00
1.3
1.5
—
—
—
0
0
8
87
0.92
-0.00
1.3
1.5
—
—
—
0
0
8
88
0.91
-0.00
1.3
1.5
—
—
—
0
0
7
73
0.96
-0.00
1.3
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
47.00
—
0
7
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
62
0.97
-0.00
1.2
1.0
—
—
—
0
0
5
57
0.88
-0.00
1.4
1.5
—
—
—
0
0
8
87
0.92
-0.00
1.3
1.5
—
—
—
0
0
8
88
0.91
-0.00
1.3
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
1.24
—
0
9
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_ERYTHRO_KELA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ERYTHRO_KELA | 1.756 [1.38, 2.24] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.201 |
During the follow-up period (1.1.1998 — 31.12.2019), 107 out of 680 females with L12_ERYTHRO_KELA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_ERYTHRO_KELA | 1.919 [1.61, 2.28] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.062 |
During the follow-up period (1.1.1998 — 31.12.2019), 254 out of 1333 males with L12_ERYTHRO_KELA died.
Mortality risk
Mortality risk for people of age
years, who have L12_ERYTHRO_KELA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.161% | 0.426% |
| 5 | 0.981% | 2.332% |
| 10 | 2.483% | 6.368% |
| 15 | 4.943% | 11.795% |
| 20 | 8.337% | 19.381% |
Relationships between endpoints
↥Index endpoint: L12_ERYTHRO_KELA – Universal erythroderma, KELA reimbursement
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data